Crinetics Reports Over $5M in Q4 2025 PALSONIFY Revenue with Strong Launch Metrics

Crinetics Pharmaceuticals reported unaudited and preliminary U.S. net product revenue of over $5 million for PALSONIFY in Q4 2025, the first full quarter post-FDA approval on September 25, 2025.1 2 3

Over 200 enrollment forms submitted and more than 125 unique prescribers engaged as of December 31, 2025.1 2 5

Approximately half of newly filled bottles were reimbursed without needing bridge supplies, with 12-month prior authorizations.1

PALSONIFY is approved for first-line treatment of adults with acromegaly inadequately responsive to surgery.1 4

Company aims for >75% payer coverage within nine months and highlighted strong launch execution.1 2

Sources:

1. https://www.stocktitan.net/news/CRNX/crinetics-announces-strong-palsonify-launch-execution-and-positive-vu58g0qgch24.html

2. https://www.marketbeat.com/instant-alerts/crinetics-pharmaceuticals-touts-5m-palsonify-q4-launch-posts-strong-atumelnant-phase-2-cah-data-2026-01-05/

3. https://www.tipranks.com/news/the-fly/crinetics-reports-q4-palsonify-u-s-preliminary-net-product-revenue-of-over-5m-thefly

4. https://crinetics.com/crinetics-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-business-update/

5. https://www.investing.com/news/analyst-ratings/baird-reiterates-outperform-rating-on-crinetics-stock-as-palsonify-launch-exceeds-expectations-93CH-4430680

Sources:

Leave a Reply Cancel reply